Highlights • Selgantolimod (SLGN) is an oral Toll-like receptor 8 agonist. • Viremic patients with chronic HBV infection received SLGN+TAF for 24 weeks. • SLGN therapy was safe and well tolerated. • SLGN induced a transient increase in serum cytokines and chemokines. • Pharmacodynamics and antiviral activity support continued study of SLGN in combination CHB therapies.
All Keywords
【저자키워드】 Immunotherapy, Toll-like receptor, small molecule, Hepatitis B virus, HBV cure, oral antiviral, viremic,
【저자키워드】 Immunotherapy, Toll-like receptor, small molecule, Hepatitis B virus, HBV cure, oral antiviral, viremic,